Soleus Capital Issues Letter to The Board of Theratechnologies
Soleus Capital, a major shareholder owning over 10% of Theratechnologies (NASDAQ: THTX), has sent a critical letter to the company's Board of Directors regarding a potential acquisition offer. The letter addresses Future Pak, 's proposal to acquire the company at $3.51 per share, representing a substantial 163% premium over the April 10th closing price.
Soleus Capital expressed concerns that THTX's management and Board have been unresponsive to potential acquirers, potentially breaching their shareholder obligations. The investment firm strongly advocates for accepting the all-cash offer, arguing it would provide greater shareholder value compared to remaining independent or pursuing alternative combinations that might prioritize management retention over shareholder interests.
Soleus Capital, un azionista di maggioranza che possiede oltre il 10% di Theratechnologies (NASDAQ: THTX), ha inviato una lettera critica al Consiglio di Amministrazione dell'azienda riguardo a un potenziale offerta di acquisizione. La lettera affronta la proposta di Future Pak di acquisire l'azienda a $3.51 per azione, che rappresenta un sostanziale premium del 163% rispetto al prezzo di chiusura del 10 aprile.
Soleus Capital ha espresso preoccupazioni riguardo al fatto che la direzione e il Consiglio di THTX siano stati poco reattivi nei confronti dei potenziali acquirenti, violando potenzialmente i loro obblighi verso gli azionisti. La società di investimento sostiene fermamente l'accettazione dell'offerta in contante, sostenendo che fornirebbe un valore maggiore per gli azionisti rispetto a rimanere indipendenti o perseguire combinazioni alternative che potrebbero dare priorità alla retention del management rispetto agli interessi degli azionisti.
Soleus Capital, un accionista mayoritario que posee más del 10% de Theratechnologies (NASDAQ: THTX), ha enviado una carta crítica a la Junta Directiva de la empresa sobre una posible oferta de adquisición. La carta aborda la propuesta de Future Pak para adquirir la empresa a $3.51 por acción, lo que representa una considerable prima del 163% sobre el precio de cierre del 10 de abril.
Soleus Capital expresó su preocupación de que la dirección y la Junta de THTX han sido poco receptivas a los posibles compradores, lo que podría violar sus obligaciones hacia los accionistas. La firma de inversión aboga firmemente por aceptar la oferta en efectivo, argumentando que proporcionaría un mayor valor a los accionistas en comparación con permanecer independientes o perseguir combinaciones alternativas que podrían priorizar la retención del management sobre los intereses de los accionistas.
솔레우스 캐피탈은 테라테크놀로지스 (NASDAQ: THTX)의 10% 이상을 보유한 주요 주주로서, 회사의 이사회에 잠재적 인수 제안에 대한 비판적인 서신을 보냈습니다. 이 서신은 퓨처 팩의 제안, 즉 주당 $3.51에 회사를 인수하겠다는 내용을 다루고 있으며, 이는 4월 10일 마감 가격에 비해 상당한 163% 프리미엄을 나타냅니다.
솔레우스 캐피탈은 THTX의 경영진과 이사회가 잠재적 인수자에게 반응이 없었으며, 이는 주주 의무를 위반할 수 있다고 우려를 표명했습니다. 이 투자 회사는 현금 전액 제안을 수용할 것을 강력히 지지하며, 이는 독립적으로 남거나 경영진 유지보다 주주 이익을 우선시할 수 있는 대체 조합을 추구하는 것보다 더 큰 주주 가치를 제공할 것이라고 주장합니다.
Soleus Capital, un actionnaire majoritaire détenant plus de 10 % de Theratechnologies (NASDAQ: THTX), a envoyé une lettre critique au Conseil d'Administration de l'entreprise concernant une offre d'acquisition potentielle. La lettre aborde la proposition de Future Pak d'acquérir l'entreprise à $3.51 par action, représentant une prime substantielle de 163% par rapport au prix de clôture du 10 avril.
Soleus Capital a exprimé des préoccupations quant au fait que la direction et le Conseil de THTX n'ont pas été réactifs aux acquéreurs potentiels, ce qui pourrait constituer une violation de leurs obligations envers les actionnaires. La société d'investissement plaide fermement en faveur de l'acceptation de l'offre entièrement en espèces, arguant que cela fournirait une valeur actionnariale supérieure par rapport au maintien de l'indépendance ou à la recherche de combinaisons alternatives qui pourraient privilégier la rétention de la direction au détriment des intérêts des actionnaires.
Soleus Capital, ein Hauptaktionär, der über 10% von Theratechnologies (NASDAQ: THTX) hält, hat einen kritischen Brief an den Vorstand des Unternehmens bezüglich eines potenziellen Übernahmeangebots gesendet. Der Brief befasst sich mit dem Vorschlag von Future Pak, das Unternehmen zu einem Preis von $3.51 pro Aktie zu erwerben, was einen erheblichen Premium von 163% gegenüber dem Schlusskurs am 10. April darstellt.
Soleus Capital äußerte Bedenken, dass das Management und der Vorstand von THTX auf potenzielle Käufer nicht reagiert haben, was möglicherweise ihre Verpflichtungen gegenüber den Aktionären verletzt. Die Investmentfirma setzt sich nachdrücklich dafür ein, das Angebot in bar anzunehmen, und argumentiert, dass dies einen größeren Wert für die Aktionäre bieten würde, als unabhängig zu bleiben oder alternative Kombinationen zu verfolgen, die möglicherweise die Beibehaltung des Managements über die Interessen der Aktionäre priorisieren.
- Potential acquisition offer at $3.51 per share, representing 163% premium
- All-cash transaction structure provides certainty for shareholders
- Management allegedly unresponsive to potential acquirers
- Possible conflict between management's interests and shareholder value maximization
In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company’s shareholders and urged the Board to pursue an acquisition offer announced earlier today by Future Pak, LLC at a price of at least
The letter also described Soleus Capital’s concern that management of the Company and the Board had repeatedly ignored and/or been unresponsive to potential interested parties who have reached out to Company management for the purpose of entering into acquisition talks, which is inconsistent with management’s and the Board’s obligations to shareholders.
Soleus stated that, given the significant premium and all-cash nature of the Future Pak offer, significantly more value would accrue to shareholders by accepting the offer rather than continuing as a standalone company or in any potential alternative combination which prioritizes management job preservation over shareholder value.
The full letter is available via this link: Letter to The Board
About Soleus Capital
Soleus Capital is a healthcare investment firm located in
Disclaimer
The views expressed in this letter represent the opinions of Soleus Capital and are based on publicly available information with respect to the Company. Soleus Capital reserves the right to change any of its opinions expressed herein at any time as it deems appropriate and disclaims any obligation to notify the market or any other party of such change. Soleus Capital disclaims any obligation to update the information or opinions contained in the linked letter.
This letter is provided merely as information and is not intended to be, nor should it be construed as investment advice, or as an offer to sell or a solicitation of an offer to buy any security. This letter does not recommend the purchase or sale of any security. Soleus Capital currently beneficially owns shares of the Company. Soleus Capital is in the business of trading – buying and selling– securities and intends to continue trading in the securities of the Company. You should assume Soleus Capital will from time to time sell all or a portion of its holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411508184/en/
Media Contact:
Anna Lowden
Anna@soleuscapital.com
Source: Soleus Capital Management, L.P.
FAQ
What is the acquisition offer price for Theratechnologies (THTX) proposed by Future Pak?
How much of Theratechnologies (THTX) does Soleus Capital own?
What are Soleus Capital's main concerns regarding THTX's management?
Why does Soleus Capital support the Future Pak acquisition of THTX?
